Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report

Published:2020-11 Issue:6 Volume:21 Page:e601-e606
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Aubanel Marjorie,Swalduz Aurélie,Avrillon Virginie,Doublet Louis,Mastroianni Bénédicte,Neidhardt-Bérard Eve-Marie,Pérol Maurice

Funder

Roche

AstraZeneca

Chugai

Takeda

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain;Pao;PLoS Med,2005

2. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017

3. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

4. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component;Yang;J Clin Oncol,2017

5. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors;Westover;Ann Oncol,2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC;JTO Clinical and Research Reports;2024-02

2. Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report;Cancer Management and Research;2023-07

3. The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC;Biomedicine & Pharmacotherapy;2022-12

4. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program;Translational Oncology;2022-01

5. Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer;Clinical Lung Cancer;2021-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3